CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: Implications for HIV/AIDS treatment

British Journal of Clinical Pharmacology

Volumn 64, Issue 3, 2007, Pages 391-395

  Mehlotra, Rajeev K ^a   Bockarie, Moses J ^b   Zimmerman, Peter A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

Author keywords

Antiretroviral drugs; CYP2B6; Efavirenz; North America; Papua New Guinea; West Africa

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOCHROME P450 2B6;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; AFRICAN AMERICAN; ALLELE; ARTICLE; ASIAN AMERICAN; CONTROLLED STUDY; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; FREQUENCY ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NORTH AMERICA; PAPUA NEW GUINEA; PHARMACOGENETICS; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AFRICAN AMERICANS; ALLELES; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; GENOTYPE; HAPLOTYPES; HIV INFECTIONS; HUMANS; OXIDOREDUCTASES, N-DEMETHYLATING; PAPUA NEW GUINEA; POLYMORPHISM, SINGLE NUCLEOTIDE; POPULATION GROUPS; UNITED STATES;

EID: 34548033928     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02884.x     Document Type: Article

References (18)

1. Fortin C, Joly V. Efavirenz for HIV-1 infection in adults: an overview. Expert Rev Anti Infect Ther 2004 2 : 671 84.
2. Milinkovic A, Martinez E. Nevirapine in the treatment of HIV. Expert Rev Anti Infect Ther 2004 2 : 367 73.
3. Ward BA, Gorski JC, Jones DR, Hall SD. Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism. implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003 306 : 287 300.
4. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999 27 : 1488 95.
5. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, Zanger UM. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001 11 : 399 415.
6. Lang T, Klein K, Richter T, Zibat A, Kerb R, Eichelbaum M, Schwab M, Zanger UM. Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther 2004 311 : 34 43.
7. Mehlotra RK, Ziats MN, Bockarie MJ, Zimmerman PA. Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol 2006 62 : 267 75.
8. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004 18 : 2391 400.
9. Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, Oka S. Homozygous CYP2B6*6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 2004 319 : 1322 6.
10. Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, Keiser O, Biollaz J, Decosterd L, Telenti A, Swiss HIV, Cohort Study. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005 15 : 1 5.
11. Rodriguez-Novoa S, Barreiro P, Rendon A, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005 40 : 1358 61.
12. Hasse B, Gunthard HF, Bleiber G, Krause M. Efavirenz intoxication due to slow hepatic metabolism. Clin Infect Dis 2005 40 : e22 3.
13. Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, Clifford DB, Marzolini C, Fletcher CV, Tashima KT, Kuritzkes DR, Acosta EP. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006 42 : 401 7.
14. Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M, Schwab M, Zanger UM. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 2005 15 : 861 73.
15. Wang J, Sonnerborg A, Rane A, Josephson F, Lundgren S, Stahle L, Ingelman-Sundberg M. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 2006 16 : 191 8.
16. Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, Dawson EP. Genetic variation in eleven phase 1 drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004 5 : 895 931.
17. Mehlotra RK, Bockarie MJ, Zimmerman PA. Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations. Eur J Clin Pharmacol 2007 63 : 1 8.
18. Gutierrez F, Navarro A, Padilla S, Anton R, Masia M, Borras J, Martin-Hidalgo A. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 2005 41 : 1648 53.